Get the Stockscreener App
91.79
0.69%
+0.63
Amedisys Inc. stock is currently priced at $91.79, with a 24-hour trading volume of 143.08K.
It has seen a +0.69% increased in the last 24 hours and a -0.54% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $91.01 pivot point. If it approaches the $92.36 resistance level, significant changes may occur.
Previous Close:
$91.16
Open:
$91
24h Volume:
143.08K
Market Cap:
$3.00B
Revenue:
$2.24B
Net Income/Loss:
$-9.75M
P/E Ratio:
1,311.29
EPS:
0.07
Net Cash Flow:
$124.48M
1W Performance:
+1.54%
1M Performance:
-0.54%
6M Performance:
+0.70%
1Y Performance:
+19.75%
1D Range:
$91.00
$91.88
52W Range:
$73.10
$96.44
Amedisys Inc. Stock (AMED) Company Profile
Name
Amedisys Inc.
Sector
Industry
Phone
225-292-2031
Address
3854 American Way, Suite A, Baton Rouge, LA
Amedisys Inc. Stock (AMED) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-07-23 | Downgrade | Truist | Buy → Hold |
| Apr-21-23 | Initiated | Cantor Fitzgerald | Neutral |
| Mar-13-23 | Initiated | Barclays | Equal Weight |
| Oct-27-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-02-22 | Downgrade | UBS | Neutral → Sell |
| Jun-29-22 | Initiated | Stifel | Hold |
| Jun-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-01-22 | Upgrade | UBS | Sell → Neutral |
| Feb-25-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-25-22 | Reiterated | Credit Suisse | Outperform |
| Feb-25-22 | Reiterated | Oppenheimer | Outperform |
| Feb-25-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-25-22 | Reiterated | Raymond James | Outperform |
| Feb-25-22 | Reiterated | Truist | Buy |
| Sep-27-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | UBS | Sell |
| Sep-10-21 | Initiated | Cowen | Market Perform |
| Aug-10-21 | Reiterated | The Benchmark Company | Buy |
| Aug-05-21 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-20-20 | Resumed | Barclays | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Buy |
| Jun-18-20 | Upgrade | The Benchmark Company | Hold → Buy |
| May-07-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Mar-09-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-17-20 | Initiated | Credit Suisse | Outperform |
| Nov-01-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-22-19 | Resumed | Stephens | Equal-Weight |
| Sep-17-19 | Initiated | Deutsche Bank | Buy |
| May-02-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-14-18 | Initiated | Barclays | Equal Weight |
| Nov-16-18 | Initiated | UBS | Neutral |
| Oct-30-18 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-03-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-19-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Nov-09-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Nov-08-17 | Reiterated | Mizuho | Buy |
| Nov-02-17 | Upgrade | The Benchmark Company | Hold → Buy |
| Aug-21-17 | Initiated | BofA/Merrill | Neutral |
View All
Amedisys Inc. Stock (AMED) Latest News
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics
Zacks Investment Research
Amedisys (AMED) Q1 Earnings and Revenues Surpass Estimates
Zacks Investment Research
Amedisys Reports First Quarter 2024 Financial Results
GlobeNewswire Inc.
Premium Growth Propels Humana (HUM) to Easy Q1 Earnings Beat
Zacks Investment Research
Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Zacks Investment Research
Here's Why Amedisys (AMED) is a Strong Value Stock
Zacks Investment Research
Amedisys Inc. Stock (AMED) Financials Data
Amedisys Inc. (AMED) Revenue 2024
AMED reported a revenue (TTM) of $2.24 billion for the quarter ending December 31, 2023, a +0.59% rise year-over-year.
Amedisys Inc. (AMED) Net Income 2024
AMED net income (TTM) was -$9.75 million for the quarter ending December 31, 2023, a -108.22% decrease year-over-year.
Amedisys Inc. (AMED) Cash Flow 2024
AMED recorded a free cash flow (TTM) of $124.47 million for the quarter ending December 31, 2023, a -1.26% decrease year-over-year.
Amedisys Inc. (AMED) Earnings per Share 2024
AMED earnings per share (TTM) was -$0.31 for the quarter ending December 31, 2023, a -108.52% decline year-over-year.
About Amedisys Inc.
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2018, the company owned and operated 421 care centers in 34 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
1.09%
0.03%
Cap:
|
Volume (24h):